TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36214599

Group type: EXPERIMENTAL
Intervention: LPG cookstove and fuel (intervention group)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Biomass cookstove (control group)
Number of subjects: 3200
Study: 33914154

Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 25

Group type: COMPARATOR
Intervention: ET
Number of subjects: 25
Study: 34776145

Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager at 25 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager at 52 Hz
Number of subjects: 14

Group type: COMPARATOR
Intervention: Myofascial release with portable electric massager (both frequencies)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Myofascial release with portable electric massager (deep layer at knee flexed 45°)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Myofascial release with portable electric massager (both layers at knee extended 0°)
Number of subjects: 14
Study: 32185692

Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP) in obese patients
Number of subjects: 219

Group type: COMPARATOR
Intervention: Controlled Attenuation Parameter (CAP) in non-obese patients
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM) in obese patients
Number of subjects: 219

Group type: COMPARATOR
Intervention: Liver stiffness measurement (LSM) in non-obese patients
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Optimal CAP cut-off values for steatosis in non-obese patients
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Optimal CAP cut-off values for steatosis in obese patients
Number of subjects: 219

Group type: COMPARATOR
Intervention: Discordance between CAP and biopsy measured steatosis in non-obese NAFLD
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Discordance between CAP and biopsy measured steatosis in obese NAFLD
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: CAP performance in predicting steatosis
Number of subjects: 219
Study: 35345661

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (Buqi Huoxue Decoction + cardiac rehabilitation care)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (conventional antiplatelet therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cardiac care group
Number of subjects: 120

Group type: COMPARATOR
Intervention: TCM + WM group (Buqi Huoxue Decoction + conventional treatment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 33975094

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patch
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 72
Study: 36106759

Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) administered as one tablet twice a day for 7 days, followed by 3 weeks of placebo for all patients.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control (WL) for 7 days, followed by 3 weeks of placebo for all patients.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) after day 8 for all patients.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Open-labeled placebo (OLP) on day 8.
Number of subjects: 84
Study: 34130676

Group type: EXPERIMENTAL
Intervention: Virtual reality-based serious gaming (VRBSG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lecture instruction
Number of subjects: 50
Study: 32650688

Group type: EXPERIMENTAL
Intervention: Central adjudication of outcomes in stroke trials
Number of subjects: 25436
Study: 35459970

Group type: EXPERIMENTAL
Intervention: Biological determinist condition
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Epigenetic condition
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 183
Study: 32141014

Group type: EXPERIMENTAL
Intervention: Tegadermâ„¢
Number of subjects: 0

Group type: COMPARATOR
Intervention: EyeGardÂ®
Number of subjects: 0
Study: 36450129

Group type: EXPERIMENTAL
Intervention: Islatravir-eluting implant (48 mg, 52 mg, or 56 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo implant
Number of subjects: 36
Study: 33331040

Group type: EXPERIMENTAL
Intervention: Novel dental gel containing 2.6% EDTA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Commercially available anti-gingivitis dentifrice with 0.454% stannous fluoride
Number of subjects: 65
Study: 34203155

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Brief salt reduction instruction by a physician
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG) - Notification of current salt intake only
Number of subjects: 0
Study: 32430458

Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 units/mL (Gla-300)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Insulin Glargine 100 units/mL (Gla-100)
Number of subjects: 463
Study: 34181880

Group type: EXPERIMENTAL
Intervention: BNT162b2 (0.3 mL) via a single intramuscular injection
Number of subjects: 676

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 676
Study: 32388273

Group type: EXPERIMENTAL
Intervention: PM10
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: O3
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: PM2.5
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: PM10 and O3
Number of subjects: 218
Study: 34796757

Group type: EXPERIMENTAL
Intervention: Initial customization with DBDM (IC + DBDM)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Initial customization of the intervention (IC-only)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Business-as-usual comparison condition
Number of subjects: 88
Study: 33761920

Group type: EXPERIMENTAL
Intervention: FTT + HPV intervention group
Number of subjects: 519

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 519
Study: 36185306

Group type: EXPERIMENTAL
Intervention: Weekly nurse monitoring phone call and educational leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational leaflet only
Number of subjects: 0
Study: 33428177

Group type: EXPERIMENTAL
Intervention: Sovateltide (0.3 µg/kg, intravenous bolus over 1 min, three doses on day 1, day 3, and day 6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sovateltide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study: 36253717

Group type: EXPERIMENTAL
Intervention: Lidocaine + propofol (Group L)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal saline + propofol (Group C)
Number of subjects: 59
Study: 32539596

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic/pharmacodynamic studies
Number of subjects: 0
Study: 32303364

Group type: EXPERIMENTAL
Intervention: Worked examples with hints (video or text)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Worked examples without hints (video or text)
Number of subjects: 147
Study: 35230203

Group type: EXPERIMENTAL
Intervention: ThePaS-I (Therapy Program for Adequate Sexual Behaviors Version 1) - offending-specific skills training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ThePaS-II (Therapy Program for Adequate Sexual Behaviors Version 2) - general socioemotional skills training
Number of subjects: 0
Study: 35576438

Group type: EXPERIMENTAL
Intervention: Telaglenastat plus Everolimus (TelaE)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo plus Everolimus (PboE)
Number of subjects: 69
Study: 33287911

Group type: EXPERIMENTAL
Intervention: Human albumin 20% (60-g loading dose over 2–3 h, followed by 40–80 g infusion to maintain serum levels at least 30 g/l for 28 days)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Usual practice with crystalloids for resuscitation and maintenance
Number of subjects: 1412
Study: 37563249

Group type: EXPERIMENTAL
Intervention: Nurse collection (venepuncture and DBS)
Number of subjects: 2162

Group type: COMPARATOR
Intervention: Self-collection (DBS)
Number of subjects: 2162

Group type: COMPARATOR
Intervention: Nurse collection (venepuncture)
Number of subjects: 2162
Study: 33969923

Group type: EXPERIMENTAL
Intervention: Lidocaine nasal spray
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 304
Study: 33327551

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic training (IHT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normoxic conditions)
Number of subjects: 30
Study: 36429591

Group type: EXPERIMENTAL
Intervention: Self-guided mAPA
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: In-person mAPA
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study: 32348832

Group type: EXPERIMENTAL
Intervention: Closer adherence to a Mediterranean diet (aMedi tertile 3)
Number of subjects: 7756

Group type: EXPERIMENTAL
Intervention: Fish consumption (quartile 4)
Number of subjects: 7756
Study: 34038293

Group type: EXPERIMENTAL
Intervention: HIIT + lifestyle education program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 41
Study: 33197659

Group type: EXPERIMENTAL
Intervention: Buteyko training (BG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 32
Study: 32362175

Group type: EXPERIMENTAL
Intervention: Personalized text message support and a checklist for initiation of antihypertensive medication
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no personalized text message support and checklist)
Number of subjects: 111
Study: 33928209

Group type: EXPERIMENTAL
Intervention: Study regimen targeting aberrant pathway (veliparib with temozolomide, adavosertib with carboplatin, everolimus, or trametinib)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control regimen not targeting aberrant pathway (one of the same four regimens)
Number of subjects: 69
Study: 32667223

Group type: EXPERIMENTAL
Intervention: Paediatric Autism Communication Therapy
Number of subjects: 18
Study: 35579410

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diode laser (n=15)
Number of subjects: 30
Study: 33746043

Group type: EXPERIMENTAL
Intervention: Virtual family-centered rounds (FCR) plus standard of care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 110
Study: 32227566

Group type: EXPERIMENTAL
Intervention: Presentation by an African American second‐year genetic counseling student with a brochure detailing the same information (presentation group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Brochure only (brochure group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 36448506

Group type: EXPERIMENTAL
Intervention: Fixation of ulnar styloid fractures (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-operative treatment of ulnar styloid fractures (Group B)
Number of subjects: 43
Study: 33651442

Group type: EXPERIMENTAL
Intervention: Oral TXA 250 mg bid
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 mg/mL intradermal TXA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg/mL intradermal TXA
Number of subjects: 45
Study: 33177272

Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 32976087

Group type: EXPERIMENTAL
Intervention: High Attributional Training (AT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low Attributional Training (AT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 34113408

Group type: EXPERIMENTAL
Intervention: Periarticular multimodal cocktail injection with betamethasone (7 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Periarticular multimodal cocktail injection without corticosteroids
Number of subjects: 60
Study: 32990618

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified salt
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control (no fortified salt)
Number of subjects: 228
Study: 35561011

Group type: EXPERIMENTAL
Intervention: Nurse-led medication adherence therapy (MAT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 85
Study: 33966891

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with morphine
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 221

Group type: COMPARATOR
Intervention: PCA
Number of subjects: 221
Study: 36055465

Group type: EXPERIMENTAL
Intervention: Strong opioid (step 3 of the WHO ladder)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Weak opioid (step 2 of the WHO ladder)
Number of subjects: 153
Study: 32994107

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of three options (no test, 5-gene, 15-gene)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Sequential presentation of options (no test, 5-gene, then 15-gene)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Incorporating a provider recommendation
Number of subjects: 454
Study: 35831058

Group type: EXPERIMENTAL
Intervention: ICSI+PGT‐A
Number of subjects: 450

Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 450
Study: 34967191

Group type: EXPERIMENTAL
Intervention: Individualised dietary guidance and anti-resistance exercise (Group C)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Individualised dietary guidance (Group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Educational seminars (Group A)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Diet and comprehensive groups (Group B and C)
Number of subjects: 78
Study: 33849683

Group type: EXPERIMENTAL
Intervention: Amphetamine 2.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amphetamine 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amphetamine 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 33968874

Group type: EXPERIMENTAL
Intervention: Community-based Muscle Strengthening Exercise (COME) program
Number of subjects: 32
Study: 32807157

Group type: EXPERIMENTAL
Intervention: Proactive peer mentor intervention plus usual care
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 12
Study: 35689521

Group type: EXPERIMENTAL
Intervention: VYC‐17.5L
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 33387550

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 27 μg clonidine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen plus IANB using 2% lidocaine with 18 μg epinephrine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 62
Study: 33578597

Group type: EXPERIMENTAL
Intervention: 2 minutes rest group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 1 minute 45 seconds rest group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 1 minute 30 seconds rest group
Number of subjects: 79

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 79
Study: 32421513

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study: 35276883

Group type: EXPERIMENTAL
Intervention: Supplemented group (GS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group (GP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 24
Study: 33448402

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (medium anti-NP, 145-299 OD units)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (high anti-NP, ≥300 OD units)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 39
Study: 32026389

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tiotropium/olodaterol (TIO/OLO) 5/5 mcg
Number of subjects: 148
Study: 33556765

Group type: EXPERIMENTAL
Intervention: Closed-loop algorithm (CLA) for DBS programming
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard of care (SOC) for DBS programming
Number of subjects: 12
Study: 32552784

Group type: EXPERIMENTAL
Intervention: Integrated disease management (IDM)
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Usual care (guideline-supported non-programmatic care)
Number of subjects: 1086
Study: 34338165

Group type: EXPERIMENTAL
Intervention: SMArT intervention
Number of subjects: 107
Study: 32726445

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Megasphaera species type 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Megasphaera species type 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Mageeibacillus indolicus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Bifidobacterium bifidum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Aerococcus christensenii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Lactobacillus mucosae
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Streptococcus equinus/infantarius/lutentiensis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Prevotella bivia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Dialister propionicifaciens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher relative abundances of Lactobacillus crispatus/helveticus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing quantities of Megasphaera species
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing quantities of M indolicus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing quantities of L crispatus
Number of subjects: 0
Study: 33291206

Group type: EXPERIMENTAL
Intervention: Portfolio assessment system
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Standardized objective assessment procedures
Number of subjects: 7
Study: 35300357

Group type: EXPERIMENTAL
Intervention: 6-session pharmacist-led intervention focusing on modifiable psychosocial factors
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 6-session pharmacist-led intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 31
Study: 32467299

Group type: EXPERIMENTAL
Intervention: SBRT + IL-2
Number of subjects: 44

Group type: COMPARATOR
Intervention: IL-2 monotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Crossover group (SBRT + IL-2)
Number of subjects: 44
Study: 36410471

Group type: EXPERIMENTAL
Intervention: Ripasudil-brimonidine fixed-dose combination (RBFC)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Ripasudil
Number of subjects: 488

Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 488
Study: 33481829

Group type: EXPERIMENTAL
Intervention: Tai Chi training for 6 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Tai Chi experts
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive dual-task walking
Number of subjects: 87
Study: 35227729

Group type: EXPERIMENTAL
Intervention: Contracted endodontic cavity (CEC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional endodontic cavity (TEC)
Number of subjects: 48
Study: 32278578

Group type: EXPERIMENTAL
Intervention: Double layer bandage
Number of subjects: 93

Group type: COMPARATOR
Intervention: Crepe bandage
Number of subjects: 93
Study: 34447181

Group type: EXPERIMENTAL
Intervention: aceclofenac + paracetamol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: lornoxicam + paracetamol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: tramadol + paracetamol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 150
Study: 33228727

Group type: EXPERIMENTAL
Intervention: CPB/DHCA + HA380 hemoperfusion
Number of subjects: 88

Group type: COMPARATOR
Intervention: CPB/DHCA only (control group)
Number of subjects: 88
Study: 33035972

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to NO2
Number of subjects: 39782

Group type: EXPERIMENTAL
Intervention: Postnatal PM10 and NO2
Number of subjects: 39782

Group type: EXPERIMENTAL
Intervention: Postnatal outdoor temperature
Number of subjects: 39782

Group type: EXPERIMENTAL
Intervention: Perinatal and current dampness, indoor mould, and cockroaches
Number of subjects: 39782

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to farm environment and large family size
Number of subjects: 39782

Group type: EXPERIMENTAL
Intervention: Chemical emissions from indoor materials after first year of life
Number of subjects: 39782
Study: 32417298

Group type: EXPERIMENTAL
Intervention: Fully covered self-expanding metal stents (FCSEMSs)
Number of subjects: 41
Study: 35853748

Group type: EXPERIMENTAL
Intervention: Goals-of-care decision aid (DA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 66
Study: 33548020

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol 200/6 μg
Number of subjects: 3366

Group type: COMPARATOR
Intervention: Maintenance budesonide 200 μg
Number of subjects: 3366

Group type: COMPARATOR
Intervention: As-needed terbutaline 0.5 mg
Number of subjects: 3366
Study: 36443750

Group type: EXPERIMENTAL
Intervention: Combined less dense laser and intra vitreal bevacizumab (IVB) treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional laser therapy
Number of subjects: 43
Study: 33954780

Group type: EXPERIMENTAL
Intervention: HPHF meal (60 g protein, 40 g fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LPLF meal (5 g protein, 5 g fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HPHF meal (0 to 2 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HPHF meal (2 to 4 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HPHF meal (4 to 5 hours)
Number of subjects: 10
Study: 32661604

Group type: EXPERIMENTAL
Intervention: Total confinement (TC)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Partial confinement (PC)
Number of subjects: 156
Study: 36474942

Group type: EXPERIMENTAL
Intervention: Online patient decision aid with individualized potential outcomes of surgery
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 163